Suppr超能文献

ARREST试验的原理与设计:研究间充质干细胞治疗小腹部主动脉瘤

Rationale and Design of the ARREST Trial Investigating Mesenchymal Stem Cells in the Treatment of Small Abdominal Aortic Aneurysm.

作者信息

Wang S Keisin, Green Linden A, Gutwein Ashley R, Drucker Natalie A, Motaganahalli Raghu L, Fajardo Andres, Babbey Clifford M, Murphy Michael P

机构信息

Division of Vascular Surgery, Department of Surgery, IU Health Center for Aortic Disease, Indiana University School of Medicine, Indianapolis, IN; VA Center for Molecular and Cellular Therapeutics in Cardiovascular Disease, Richard L. Roudebush VA Medical Center, Indianapolis, IN.

Division of Vascular Surgery, Department of Surgery, IU Health Center for Aortic Disease, Indiana University School of Medicine, Indianapolis, IN; VA Center for Molecular and Cellular Therapeutics in Cardiovascular Disease, Richard L. Roudebush VA Medical Center, Indianapolis, IN.

出版信息

Ann Vasc Surg. 2018 Feb;47:230-237. doi: 10.1016/j.avsg.2017.08.044. Epub 2017 Sep 13.

Abstract

BACKGROUND

Abdominal aortic aneurysms (AAAs) are a major source of morbidity and mortality despite continuing advances in surgical technique and care. Although the inciting factors for AAA development continue to be elusive, accumulating evidence suggests a significant periaortic inflammatory response leading to degradation and dilation of the aortic wall. Previous human trials have demonstrated safety and efficacy of mesenchymal stem cells (MSCs) in the treatment of inflammation-related pathologies such as rheumatoid arthritis, graft versus host disease, and transplant rejection. Therefore, herein, we describe the Aortic Aneurysm Repression with Mesenchymal Stem Cells (ARREST) trial, a phase I investigation into the safety of MSC infusion for patients with small AAA and the cells' effects on modulation of AAA-related inflammation.

METHODS

ARREST is a phase I, single-center, double-blind, randomized controlled trial (RCT) investigating infusion both dilute and concentrated MSCs compared to placebo in 36 small AAA (35-45 mm) patients. Subjects will be followed by study personnel for 12 months to ascertain incidence of adverse events, immune cell phenotype expression, peripheral cytokine profile, and periaortic inflammation. Maximum transverse aortic diameter will be assessed regularly for 5 years by a combination of computed tomography and duplex sonography.

RESULTS

Four patients have thus far been enrolled, randomized, and treated per protocol. We anticipate the conclusion of the treatment phase within the next 24 months with ongoing long-term follow-up.

CONCLUSIONS

ARREST will be pivotal in assessing the safety of MSC infusion and provide preliminary data on the ability of MSCs to favorably modulate the pathogenic AAA host immune response. The data gleaned from this phase I trial will provide the groundwork for a larger, phase III RCT which may provide the first pharmaceutical intervention for AAA.

摘要

背景

尽管手术技术和护理不断进步,但腹主动脉瘤(AAA)仍是发病和死亡的主要原因。虽然AAA发生的诱发因素仍不明确,但越来越多的证据表明,主动脉周围存在显著的炎症反应,导致主动脉壁降解和扩张。先前的人体试验已证明间充质干细胞(MSC)在治疗类风湿性关节炎、移植物抗宿主病和移植排斥等炎症相关病症方面的安全性和有效性。因此,在本文中,我们描述了间充质干细胞抑制主动脉瘤(ARREST)试验,这是一项针对小AAA患者进行MSC输注安全性及细胞对AAA相关炎症调节作用的I期研究。

方法

ARREST是一项I期、单中心、双盲、随机对照试验(RCT),在36例小AAA(35 - 45毫米)患者中,将稀释和浓缩的MSC输注与安慰剂进行比较。研究人员将对受试者进行12个月的随访,以确定不良事件的发生率、免疫细胞表型表达、外周细胞因子谱和主动脉周围炎症。通过计算机断层扫描和双功超声检查相结合的方式,对最大主动脉横径进行为期5年的定期评估。

结果

到目前为止,已有4例患者按照方案入组、随机分组并接受治疗。我们预计在未来24个月内完成治疗阶段,并进行持续的长期随访。

结论

ARREST对于评估MSC输注的安全性至关重要,并将提供关于MSC有利调节致病性AAA宿主免疫反应能力的初步数据。从这项I期试验中收集的数据将为更大规模的III期RCT奠定基础,该试验可能会为AAA提供首个药物干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验